Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFRα1, gene

被引:24
作者
Boger, Heather A. [1 ]
Middaugh, Lawrence D. [1 ,2 ]
Zaman, Vandana [1 ]
Hoffer, Barry [3 ]
Granholm, Ann-Charlotte [1 ]
机构
[1] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA
[3] Natl Inst Drug Abuse, Intramural Res Program, Baltimore, MD USA
关键词
Growth factor receptor; Aging; Neurodegeneration; Neuroinflammation; Dopamine neurotoxin;
D O I
10.1016/j.brainres.2008.09.011
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Glial cell line-derived neurotrophic factor (GDNF), a member of the transforming factor beta (TGF) superfamily, is a potent neurotrophic protein promoting the maintenance of dopaminergic (DA) neurons in the substantia nigra during adulthood. DA neurons that project to the striatum in the nigrostriatal pathway GDNF receptors, GFR alpha 1. The purpose of this study was to determine whether these are especially sensitive to neurotoxic insults. Therefore, we examined effects dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on and DA neurons in 26-month-old male GFR alpha 1 heterozygous (GFR alpha 1(+/-)) mice aged-matched wild-type (WT) littermates. MPTP gave rise to increased locomotion, of genotype, while GFR alpha 1(+/-) mice treated with saline exhibited lower spontaneous compared to WT mice. Moreover, GFR alpha 1(+/-) saline mice had fewer TH-positive greater expression of inflammatory markers (CD45 immunostaining and phosphorylated p38 MAPK) in the nigra, and reduced striatal TH staining. MPTP exacerbated these with the lowest density of striatal TH and highest density of nigral CD45 and MAPK immunoreactivity observed in GFR alpha 1(+/-) mice. The findings point to sensitivity of the DAergic system with age and neurotoxic exposure as a result of a reduction of GFR alpha 1. Published by Elsevier B.V.
引用
收藏
页码:18 / 28
页数:11
相关论文
共 74 条
  • [11] Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model
    Czlonkowska, A
    Kohutnicka, M
    Kurkowska-Jastrzebska, I
    Czlonkowski, A
    [J]. NEURODEGENERATION, 1996, 5 (02): : 137 - 143
  • [12] Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model
    Dowd, E
    Monville, C
    Torres, EM
    Wong, LF
    Azzouz, M
    Mazarakis, ND
    Dunnett, SB
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2005, 22 (10) : 2587 - 2595
  • [13] Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease
    Du, YS
    Ma, ZZ
    Lin, SZ
    Dodel, RC
    Gao, F
    Bales, KR
    Triarhou, LC
    Chernet, E
    Perry, KW
    Nelson, DLG
    Luecke, S
    Phebus, LA
    Bymaster, FP
    Paul, SM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (25) : 14669 - 14674
  • [14] Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo
    Du, Yunlan
    Li, Xuping
    Yang, Dehua
    Zhang, Xiaojie
    Chen, Shen
    Huang, Kaixing
    Le, Weidong
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2008, 233 (07) : 881 - 890
  • [15] GFRα1-deficient mice have deficits in the enteric nervous system and kidneys
    Enomoto, H
    Araki, T
    Jackman, A
    Heuckeroth, RO
    Snider, WD
    Johnson, EM
    Milbrandt, J
    [J]. NEURON, 1998, 21 (02) : 317 - 324
  • [16] Dentate granule neuron apoptosis and glia activation in murine hippocampus induced by trimethyltin exposure
    Fiedorowicz, A
    Figiel, L
    Kaminska, B
    Zaremba, M
    Wilk, S
    Oderfeld-Nowak, B
    [J]. BRAIN RESEARCH, 2001, 912 (02) : 116 - 127
  • [17] NEUROGLIAL RESPONSES TO THE DOPAMINERGIC NEUROTOXICANT 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE IN MOUSE STRIATUM
    FRANCIS, JW
    VONVISGER, J
    MARKELONIS, GJ
    OH, TH
    [J]. NEUROTOXICOLOGY AND TERATOLOGY, 1995, 17 (01) : 7 - 12
  • [18] Gainetdinov RR, 1997, J NEUROCHEM, V69, P1322
  • [19] Garcès A, 2000, J NEUROSCI, V20, P4992
  • [20] Functional recovery in parkinsonian monkeys treated with GDNF
    Gash, DM
    Zhang, ZM
    Ovadia, A
    Cass, WA
    Yi, A
    Simmerman, L
    Russell, D
    Martin, D
    Lapchak, PA
    Collins, F
    Hoffer, BJ
    Gerhardt, GA
    [J]. NATURE, 1996, 380 (6571) : 252 - 255